NUDCD2

Across TCGA pan-cancer cohorts, NUDCD2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated NUDCD2 data layer compared with 23 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher NUDCD2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated NUDCD2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

CCRCC, LSCC, and PDAC are the cancer types where NUDCD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	III,IV	1.000	0.715	.009	18	view →
LSCC	DFS	Median	III,IV	0.573	0.990	.007	15	view →
PDAC	OS	Median	II,III,IV	0.752	0.943	.004	13	view →
UCEC	OS	Median	III,IV	0.348	0.889	.037	8	view →
LUAD	DFS	Median	III,IV	0.409	0.941	.010	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

NUDCD2–CCRCC (DFS)

Open the CCRCC breakdown →